The Global Lymphedema Diagnostic market was valued at $xx Mn in 2020 and is expected to reach $xx Mn by 2027, at a CAGR of xx%.
Lymphedema is a chronic and progressive disorder resulting from impaired lymphatic system function. In developed countries, upper extremity lymphedema is mainly the consequence of breast cancer surgery in which axillary lymph node dissection and radiation alter upper extremity lymphatic flow. Diagnosis of lymphedema is made clinically. Although there is no unique sign or criteria for defining LE, the diagnosis is usually made clinically by a thorough evaluation and physical examination. Family history is important in the diagnosis of primary LE. The main symptoms are chronic swelling, progressive atrophic skin changes, and recurrent infections. It is important to identify whether the swelling is transient or persistent.
The lymphedema diagnostics market in developing regions is witnessing a growth in terms of its adoption rate, due to increasing cases of lymphedema, rising prevalence of cancer, and advancement in diagnostic methods. Prevalence estimates for lymphedema are relatively high, yet its prevalence is likely underestimated. Attempts to identify the population impact of lymphedema are hampered by the fact that this chronic, debilitating disease is frequently under-recognized or misdiagnosed. Recent prevalence estimates suggest that chronic edema is present between 1.33 per thousand5 to 1.44 per thousand.
The growing prevalence of lymphedema and cancer is a major driver for the market to elevate. Moreover, technological advancements in diagnostic equipment by industries are also expected to boost the market. The increase in advancements is encouraging stakeholders to invest more in the market. Increasing government funds and grants by private organizations are increasing the revenue share of the market. Lymphedema can also be cancer-associated such as lung cancer and breast cancer. The increasing cases of cancer-associated lymphedema are also expected to propel the market. Primary lymphedema is considered to be in around 1.3 children per 10,000 births in North America. Moreover, the population aged over the age of 65 years of age is known to be significantly affected.
However, the high cost of diagnostic imaging systems, limited supply of helium, and the short half-life of radiopharmaceuticals are restraining the market growth.
Scope of the Global Lymphedema Diagnostic market : Inquire before buying
The report contains a detailed analysis of the Strengths, Weaknesses, and opportunities of the key players operating in the Global Lymphedema Diagnostic market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers, and the key challenges.
The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques.
Global Lymphedema Diagnostic market Segment Analysis
The Lymphoscintigraphy segment is expected held the largest share of xx% in 2020 and is expected to grow at a CAGR of xx% in the forecast period.
Lymphoscintigraphy is a special type of nuclear medicine imaging that provides pictures called scintigrams of the lymphatic system. Nuclear medicine imaging uses small amounts of radioactive material to diagnose, evaluate or treat a variety of diseases. These include many types of cancers, heart disease, gastrointestinal, endocrine, or neurological disorders, and other abnormalities. Because nuclear medicine exams can pinpoint molecular activity, they have the potential to identify disease in its earliest stages. They can also show whether a patient is responding to treatment. Easy reproducibility of this technique is considered to be a major factor driving the market. Also, Lymphoscintigraphy does not directly affect the lymphatic vascular epithelium is a key factor for this segment to elevate.
By disease type, cancer is the fastest-growing segment. The increasing prevalence of cancer-associated lymphedema cases is helping the market to grow at a faster pace. Also, awareness about the early diagnosis is associated with market growth.
Based on end-users, the hospital segment is accounted for the largest share of the market in 2020. The large share of this segment can be attributed to a large number of lymphedema diagnostic procedures performed in hospitals, the growing adoption of minimum invasive procedures, and the rising adoption of advanced imaging procedures to improve workflow efficiency in hospitals.
Global Lymphedema Diagnostic market
To know about the Research Methodology :- Request Free Sample Report
Global Lymphedema Diagnostic market Segmentation
The Global Lymphedema Diagnostic market is segmented based on-
Global Lymphedema Diagnostic market Technology
• Lymphoscintigraphy
• X-ray Lymphography
• Computed Tomography
• Magnetic Resonance Imaging
• Fluorescein Sodium Micro lymphangiography
• Ultrasound Imaging
• ICG Lymphography
• Bio impedance Analysis
• Near-infrared Fluorescence Imaging
Global Lymphedema Diagnostic market Disease Type
• Cardiovascular Diseases
• Cancer
• Inflammatory Diseases
• Others
Global Lymphedema Diagnostic market End-user
• Hospitals
• Diagnostic Centers
• Research and Academic Centers
• Others
Global Lymphedema Diagnostic market Regional Insights
For More Information Visit :https://www.maximizemarketresearch.com/market-report/global-lymphedema-diagnostic-market/83601/
North America accounted for the largest share of xx% in 2020, the reason being the rising prevalence of cancer-associated lymphedema. Growth in insurance coverage in the U.S. has increased the burden on the country’s healthcare system, which has highlighted the need for improving efficiency and management of work in North America. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth. Investments by key players in this field have boosted the market growth. Rising adoption of technologically advanced diagnostic imaging systems for lymphedema is rapidly growing the market.
The Asia Pacific is also expected to witness significant growth during the forecast period due to the increasing geriatric population and rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected to drive the market demand.
Key Players operating the Global Lymphedema Diagnostic market
• Siemens Healthineers
• GE Healthcare
• Stryker Corporation
• Mindray Medical International, Ltd.
• Philips
• Canon, Inc
• Shimazdu Corporation
• Fluoptics United Imaging Healthcare Co, Ltd
• Hitachi Ltd
• Esaote
• SpA
• Neusoft Corporation
• Mindray Medical International Ltd
• Mitaka, Inc
• Curadel, LLC
• ImpediMed Ltd
The report also helps in understanding Global Lymphedema Diagnostic market dynamics, structure by analysing the market segments and project Global Lymphedema Diagnostic market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Lymphedema Diagnostic market make the report investor’s guide.
This Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.